- Measurable multiple myeloma
|
Randomized 1:1
|
Carfilzomib
|
- Confirmed disease progression
|
- ECOG performance status 0-2
|
Stratified based on:
|
Cycle 1:
|
- Long-term follow-up assessments every 8 weeks until death or study closure
|
- ≥3 prior therapeutic regimens
|
- 3 vs 4 vs ≥ 5 therapies
|
20 mg/m2 IV D 1,2
| |
- Responsive to ≥1 line of therapy
|
- Europe vs non-Europe
|
27 mg/m2 IV D 8, 9, 15, 16
| |
- Relapsed while on or after 1 therapy
| |
Cycle 2-9:
| |
- Refractory to most recent regimen
| |
27 mg/m2 IV D 1, 2, 8, 9, 15, 16
| |
| |
Cycle ≥10:
| |
| |
27 mg/m2 IV D 1, 2, 15, 16
| |
| |
Best Supportive Care Regimen
| |
| |
Prednisolone 30 mg QOD
| |
| |
OR
| |
| |
Dexamethasone 6 mg PO QOD
| |
| |
plus optional
| |
| |
Cyclophosphamide 50 mg PO QD
| |
| |
(max 1400 mg/cycle)
| |